These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11443537)

  • 1. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
    Maes M; Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Meltzer H
    Mol Psychiatry; 2001 Jul; 6(4):475-80. PubMed ID: 11443537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
    Maes M; Capuron L; Ravaud A; Gualde N; Bosmans E; Egyed B; Dantzer R; Neveu PJ
    Neuropsychopharmacology; 2001 Feb; 24(2):130-40. PubMed ID: 11120395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J; Costisella O; Canva V; Imbenotte M; Duhamel A; Lhermitte M
    Encephale; 2009 Oct; 35(5):477-83. PubMed ID: 19853722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C.
    Maes M; Bonaccorso S
    Acta Psychiatr Scand; 2004 Feb; 109(2):126-31. PubMed ID: 14725594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
    Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Verkerk R; Meltzer H; Maes M
    J Clin Psychopharmacol; 2002 Feb; 22(1):86-90. PubMed ID: 11799348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
    Bonaccorso S; Puzella A; Marino V; Pasquini M; Biondi M; Artini M; Almerighi C; Levrero M; Egyed B; Bosmans E; Meltzer HY; Maes M
    Psychiatry Res; 2001 Dec; 105(1-2):45-55. PubMed ID: 11740974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.
    Van Gool AR; Van Ojik HH; Kruit WH; Mulder PG; Fekkes D; Bannink M; Scharpé S; Stoter G; Eggermont AM; Maes M; Verkerk R
    J Interferon Cytokine Res; 2004 Jul; 24(7):411-5. PubMed ID: 15296652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
    Kenis G; Prickaerts J; van Os J; Koek GH; Robaeys G; Steinbusch HW; Wichers M
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):247-53. PubMed ID: 20667172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
    Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K
    Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
    Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
    Baranyi A; Meinitzer A; Putz-Bankuti C; Stauber R; Kapfhammer HP; Rothenhäusler HB
    Psychosom Med; 2014 Apr; 76(3):197-207. PubMed ID: 24608038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C.
    Małyszczak K; Inglot M; Frydecka D; Hadryś T; Pawłowski T
    Adv Clin Exp Med; 2019 Sep; 28(9):1217-1222. PubMed ID: 30811903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
    Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
    Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
    Amodio P; De Toni EN; Cavalletto L; Mapelli D; Bernardinello E; Del Piccolo F; Bergamelli C; Costanzo R; Bergamaschi F; Poma SZ; Chemello L; Gatta A; Perini G
    J Affect Disord; 2005 Jan; 84(1):93-8. PubMed ID: 15620390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms.
    Udina M; Moreno-España J; Navinés R; Giménez D; Langohr K; Gratacòs M; Capuron L; de la Torre R; Solà R; Martín-Santos R
    Psychoneuroendocrinology; 2013 Sep; 38(9):1803-13. PubMed ID: 23571152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C.
    Firneisz G; Lakatos PL; Szalay F;
    Scand J Gastroenterol; 2001 Aug; 36(8):877-80. PubMed ID: 11495085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z; Delić D; Marić NP; Vuković O; Jašović-Gašić M
    Psychiatr Danub; 2011 Dec; 23(4):370-7. PubMed ID: 22075738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C.
    Malaguarnera M; Laurino A; Di Fazio I; Pistone G; Castorina M; Guccione N; Rampello L
    J Interferon Cytokine Res; 2001 May; 21(5):273-8. PubMed ID: 11429157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
    Neri S; Pulvirenti D; Bertino G
    Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.